Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | -0.02 | 0.05 |
| FCF Yield | -14.86% | -70.05% | -63.24% | -31.17% |
| EV / EBITDA | -4,289.59 | -0.57 | 0.60 | -0.05 |
| Quality | ||||
| ROIC | -0.02% | -134.58% | -63.97% | -36.61% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.99 | 1.09 | 0.80 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.58% | 7.91% | 44.48% | 44.22% |
| Free Cash Flow Growth | 81.03% | -24.20% | 6.98% | -17.15% |
| Safety | ||||
| Net Debt / EBITDA | 5,909.00 | 1.05 | 1.78 | 2.97 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1.35 | 0.00 | 90.00 | 0.00 |